Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma

BMS, Sanofi Reveal Layoffs As They Right-Size R&D

Restructuring Edition: Even big pharma companies are not immune from workforce reductions. BMS and Sanofi joined that ranks of Evotec, CureVac and BenevolentAI in cutting jobs. Also, Vaxxinity will de-list and Hepion winds down its NASH trial, among other strategic updates.

Finance Watch Image — • Source: Shutterstock

Bristol Myers Squibb Company and Sanofi recently joined the ranks of companies cutting costs and jobs in 2024, although not necessarily for the same reasons, as first quarter earnings season got under way in late April.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Genentech To Try Repertoire’s Immune Synapse Technology In Autoimmune Disease

23 Apr 2025

• By Joseph Haas

Deal snapshot: The Flagship portfolio firm will use its Decode platform to seek novel targets for an unspecified autoimmune disease, with Genentech holding license rights.

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

23 Apr 2025

• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

22 Apr 2025

• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

Enzene Sees Tariff Exemptions For India, Front-Ends US Capacity

22 Apr 2025

• By Vibha Ravi

Enzene's CEO Himanshu Gadgil anticipates exemptions for Indian products from US tariffs expected to be imposed on pharmaceuticals. In an interview ahead of the US Vice Premier's India visit, he also talks about front-loading capacity at Enzene's US plant and a change in its biosimilars strategy

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

23 Apr 2025

• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.